Search companies

Live

AVITA MEDICAL INC. (ASX: AVH)

Health care · News and insights

AVH: $4.50 -2.60% · MC: $778M

Latest AVH announcements

Announcement Insights

AVITA Raises 2026 Revenue Outlook Again as Sales Growth Accelerates

AVITA Medical raised its 2026 revenue forecast for a second time, to US$92 million–US$94 million, after third-quarter revenue increased 53% year on year; it reaffirmed expected cash-flow breakeven in the fourth quarter. The November 9 update repeated that outlook rather than representing another increase, while the company also reported six-month Cohealyx study results, extending findings previously reported in April.

Updated 17 Nov 2026, 08:42 AM Sydney time
Share
SourcesAVITA Medical Reports Complete Cohealyx I DataCleansing NoticeNotification regarding unquoted securities - AVHAVITA Medical to Host Investor Webinar BriefingAVITA Medical Investor Presentation November 2026AVITA announce CMS Finalized Valuations and Codes for RECELLAVITA Medical Announces Q3 2026 Financial ResultsAVITA Q3 Financial Results Earning PresentationAVITA 10Q Quarterly Reports for Q3 2026Statement of CDIs on issue - AVHNotification regarding unquoted securities - AVHNotification regarding unquoted securities - AVHCleansing Notice
Comments

AVITA Medical Reports Six-Month Cohealyx Wound-Healing Results

2026-11-17 · Health care

AVH: $4.50 -2.60% · MC: $778M

AVITA Medical reported six-month follow-up from its Cohealyx I study, with 88% of patients assessed showing wound healing eight weeks after grafting and scar scores improving by week 26; no Cohealyx-related adverse events were reported. The study also found median graft readiness at 11 days, with 72% of wounds ready within two weeks, extending results previously reported in April.

Updated 2026-11-17 08:26
Share
SourcesAVITA Medical Reports Complete Cohealyx I Data
Comments

AVITA Medical Reiterates Raised Revenue Guidance Ahead of Investor Webinar

2026-11-09 · Health care

AVH: $4.89 +7.47% · MC: $778M

AVITA Medical’s investor presentation reiterates its 2026 revenue guidance of US$92 million to US$94 million, raised last week from US$86 million to US$89 million. The company continues to expect cash flow breakeven in the fourth quarter. Third-quarter revenue rose 53% from a year earlier to US$26 million, while the net loss more than halved to US$6 million. Chief executive Cary Vance and chief financial officer David O’Toole will discuss the results at an investor webinar on Thursday, Australian time, followed by a question-and-answer session.

Updated 2026-11-09 10:33
Share
SourcesAVITA Medical to Host Investor Webinar BriefingAVITA Medical Investor Presentation November 2026
Comments

AVITA Raises 2026 Revenue Guidance Again After Quarterly Sales Jump

2026-11-06 · Health care

AVH: $4.55 -1.73% · MC: $778M

AVITA Medical lifted its 2026 revenue forecast for a second time, to approximately $92 million–$94 million, from $86 million–$89 million, after third-quarter revenue rose 53% year on year and 20% from the previous quarter. It reaffirmed its expectation of cash-flow breakeven in the fourth quarter; separately, Medicare finalized national physician payment valuations and a simpler billing-code structure for RECELL procedures from 2027.

Updated 2026-11-06 12:01
Share
SourcesAVITA Medical Announces Q3 2026 Financial ResultsAVITA Q3 Financial Results Earning PresentationAVITA 10Q Quarterly Reports for Q3 2026AVITA announce CMS Finalized Valuations and Codes for RECELLStatement of CDIs on issue - AVH
Comments

AVITA Medical Reports Shares Issued Following Option Exercises

2026-11-05 · Health care

AVH: $4.63 +6.19% · MC: $778M

AVITA Medical reported issuing approximately 70,000 common shares in October following the exercise of unquoted options. The filing follows a separate issue of approximately 388,000 shares to Perceptive Credit Holdings V after its cashless exercise of a warrant linked to a credit facility.

Updated 2026-11-05 10:21
Share
SourcesNotification regarding unquoted securities - AVH
Comments

AVITA Medical Issues Shares After Lender Exercises Warrant

2026-11-03 · Health care

AVH: $4.32 -2.26% · MC: $778M

AVITA Medical issued 387,716 shares to Perceptive Credit Holdings V, LP after the lender cashlessly exercised a warrant for up to 500,000 shares, with the company withholding shares to cover the exercise price. The shares were issued in connection with a previously disclosed credit facility and are quoted on Nasdaq, with conversion into ASX-listed depositary interests available to the holder.

Updated 2026-11-03 08:38
Share
SourcesCleansing NoticeNotification regarding unquoted securities - AVH
Comments